Title:

<u>Development and Validation of the Cannabis Exposure in Pregnancy Tool (CEPT)</u>

Kathleen H. Chaput PhD[1,2], Carly A. McMorris PhD[3], Amy Metcalfe PhD[1,2] Catherine Ringham

PhD, Stephen Wood MD[1], Deborah McNeil PhD[2,5], Sheila W. McDonald PhD[2,6]

1. Department of Obstetrics and Gynecology, Cumming School of Medicine, University of

Calgary

2. Department of Community Health Sciences, Cumming School of Medicine University of

Calgary

3. Werklund School of Education, School and Child Psychology, University of Calgary

5. Maternal Newborn Child and youth Strategic Clinical Network, Alberta Health Services

6. Research and Innovation Population, Public, and Indigenous Health, Alberta Health Services

Correspondence:

Kathleen H. Chaput

1403 29 Street NW

Calgary, Alberta, T2N 2T9

Phone: 1-403-944-4009; email:khchaput@ucalgary.ca

Funding statement: This project was funded by a competitive research grant from the Alberta

Children's Hospital Research Institute, University of Calgary.

Competing interests: No Authors have competing interests to declare.

Word count: 2868

Abstract: (250 words)

Background: Evidence of the associations between prenatal cannabis exposure and maternal,

infant, and child health outcomes remains conflicting amid broad legalization of cannabis across

Canada and 40 American states. A primary critical limitation of existing evidence lies in the non-

standardized and crude measurement of prenatal cannabis exposure, resulting in high risk of

misclassification bias. We developed a standardized tool to comprehensively measure prenatal

cannabis use in pregnant populations for research purposes.

Methods: We conducted a patient-oriented tool development and validation study using a six-

step, bias-minimizing process. Following an environmental scan and critical appraisal of existing

prenatal substance use tools, we recruited pregnant past- present- and non-cannabis users via

targeted social media advertising and obstetric clinics in Alberta, Canada. We conducted

individual in-depth interviews and cognitive interviewing in separate sub-samples, to develop

and refine our tool. We assessed content, convergent and discriminant validity, internal

consistency and 3-month test-retest reliability, and validated externally against urine THC

bioassay at multiple timepoints in pregnancy.

Results: 194 pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool

(CEPT) had excellent discriminant (Cohen's kappa=-0.27 to 0.15) and convergent (Cohen's

kappa=0.72 to 1.0) validity; as well as high internal consistency (Chronbach's alpha = 0.92), and

very good test-retest reliability (weighted Kappa=0.92, 95% C.I. [0.86 – 0.97]). The CEPT is valid

against gold-standard urine THC bioassay (sensitivity 77%, specificity 100%) in preliminary

analyses.

Interpretation: Developed for research purposes, the CEPT is a novel, valid and reliable

measure of frequency, timing, dose, and mode of prenatal cannabis exposure, in a

contemporary sample of pregnant women. Use of the CEPT can improve measurement

accuracy, and thus the quality of research examining associations between antenatal cannabis

use and maternal and child health outcomes.

Background:

Following cannabis legalization in Canada, prenatal cannabis use is rising (1,2). Despite recent

studies of prenatal cannabis use and adverse maternal, infant, and child outcomes (3–6), the

evidence remains conflicting (7–12). A critical limitation of published studies is a high risk of

misclassification bias, resulting from a lack of standardized measurement of cannabis exposure

across adequate domains, including frequency, dose, modes, timing of use in pregnancy, and

second-hand smoke and vapour. Canadian and United States (US) governments highlight an

urgent need for high-quality cannabis-related health research and endorse pregnant individuals

and infants as priority populations (9,10,13). Improved options for measuring prenatal cannabis

use are a key component to improving the quality of the evidence.

Current prenatal cannabis-use measurement options available for research include

administrative data collected during routine prenatal care, substance use disorder (SUD)

screening tools, non-validated questionnaires, and biological tests. Administrative data is

problematic because pregnant people are known to conceal or under-report prenatal substance

use to physicians (14,15). Further, cannabis use screening is not standardized practice, occurs

variably, and is seen as low-priority for the majority of obstetricians (16). While Canadian

studies using administrative data have reported prenatal cannabis-use prevalence between 2%

and 3% (2–4), emerging evidence from an *anonymous* population-based survey indicates 11%

prevalence of prenatal cannabis use (17), and in a US study only 36% of women with cannabis-

positive urine tests had reported their use to a care provider (18), indicating that the majority

of prenatal cannabis users may be misclassified in administrative data studies.

While self-administered research questionnaires have proven to garner more accurate

reporting of substance (e.g. alcohol) use in pregnancy than screening in clinical settings (19,20),

non-standardized survey questions have limited utility for measurement of prenatal cannabis

use, as they can unintentionally convey perceived bias against prenatal cannabis use. They

often identify cannabis as an illicit drug and do not differentiate between medicinal and

recreational use, which contradicts social perception and may increase response bias (18,21).

Survey questions are problematic for studying nuanced associations with maternal and infant

health outcomes due to inconsistent assessment of frequency and timing of use, including

changing patterns through pregnancy, and often lack dose measurement, or use subjective

dose-terminology (9,10,22–28). Further, most lack measurement of potentially important

consumption modes aside from smoking (vapourized, edible, topical, second-hand)(22–24).

Standardized SUD screening tools aim to detect a diagnosable SUD, and do not measure

patterns of consumption of specific substances like cannabis throughout pregnancy (29). Many

screen for alcohol misuse alone (30–33), or combine all drugs into a single category (29)

preventing the separate evaluation of cannabis-related health outcomes. While biological

(urine/blood/saliva) cannabis-screeners exist they are limited to detection within 1-5 weeks of

use, depending on individual metabolism and test cut-off levels (34–38). Biological samples are

also resource-intensive and stigmatizing to collect, limiting their utility for prospective research.

Our study developed and validated a novel prenatal cannabis use measurement tool,

that addresses the limitations of current measurement methods, and uses a patient-oriented

approach in order to identify patient-perceived stigma, and methods of reducing perceptions of

stigma and other sources of response bias, using a six-step, peer-reviewed process (39).

Methods:

We recruited pregnant, past- and current-cannabis users and non-users, <36 weeks' gestation,

between 08/2019 and 04/2020 for this mixed-methods tool development and validation study.

We used social media advertising targeted to women aged 18-45, residing in Alberta, with listed

interests or group memberships related to pregnancy, parenting, and/or cannabis, and posted

gender-neutral recruitment ads in an online trans-gender parent support group. Study

recruitment letters were also mailed to patients who visited Alberta Health Services (AHS)

clinics for pregnancy-related care in the preceding six months, identified using pregnancy-

related codes in the National Ambulatory Care Reporting System (NACRS)(Appendix A). Our

target sample size of 150 participants was sufficient to detect a Cronbach's alpha of $\geq$0.9, with

95% confidence for test-retest reliability on a tool that contains up to 15 items (39). This study

was approved by the Conjoint Health Research Ethics Board at the University of Calgary (REB19-

0670), and Written informed consent was obtained from all participants.

Step 1 Qualitative Interviews: A crucial step often overlooked in tool development is the use of

qualitative methods to provide patient perspective, and ensure appropriate wording and

response options (49). We conducted *individual in-depth interviews* (IDIs) with 10 participants

purposively selected from the full sample, to represent regular and occasional cannabis users,

and non-users (Figure 1). Two female research assistants with training in qualitative

interviewing conducted telephone interviews at a time chosen by the participant about

participant views and experiences with cannabis use in general, and during pregnancy. Prior to

IDIs, participants had two points of contact with research staff to discuss study details,

questions, concerns, and confidentiality. Research assistants then established a trusting

relationship, by disclosing their own connections to the study topic, emphasizing a non-

judgmental approach, acknowledging that all experiences shared were important, and

guaranteeing privacy of information. We recorded and transcribed interviews verbatim, and

used deductive thematic analysis to extract pre-determined themes of: language around

cannabis and its use; perceptions of stigma and judgement, and their relations to truthful

disclosure of use; patterns of use in pregnancy (timing, frequency of use, typical dose);

motivations for use; and forms of cannabis used in the qualitative transcripts. Two team

members experienced in qualitative methods coded salient content that corresponded to the

pre-determined themes, and then collapsing codes into broader themes using constant

comparison technique, discussion and consensus. Themes were then reported back to the

qualitative participants via email for member-checking of the relevance and appropriateness of

the qualitative findings to ensure truth value.

Step 2 Devising Items: We devised items, including wording, to form the initial tool based on

strengths and shortcomings identified in existing SUD tools and published survey questions

(Table 1), and on themes identified from IDIs to form a draft tool. We eliminated double-

barreled questions, ambiguous wording and ensured a 6th grade reading level.

Step 3 Cognitive interviewing and bias reduction: Schwartz and Oyserman(40) propose five

stages of cognition required to accurately self-report behaviour, each of which are susceptible

to bias: 1. question understanding, 2. recalling relevant behaviour, 3. inference & estimation, 4.

mapping answer onto response options, and 5. answer editing. In order to identify points of

bias at all five stages of cognition, we then contacted an additional sub-sample of participants

from the full sample, and conducted individual *cognitive interviews,* in which respondents were

asked to think aloud, and share impressions, understanding and reasoning related to each of

the five stages of cognition, as we administered the newly developed tool.(41) We iteratively

revised items according to each participant's feedback prior to each subsequent interview. This

process was repeated until no new suggestions for revision were made in two consecutive

interviews. This occurred after the 17th cognitive interview.

Step 4 Face and Content Validation: We then formatted the refined items into the CEPT online

tool and sent it to a panel of experts in epidemiology, addictions, obstetrics, neonatology,

pediatrics and neurodevelopment with research and clinical interests in prenatal substance

exposure and child health, identified using and environmental scan and from our team's

professional networks. They were asked to assess whether the tool adequately captured all

domains of measurement that are critical to prospective research on the associations between

prenatal cannabis use and maternal and infant health.

Step 5 Covergent and Discriminant Validation: We then administered the finalized CEPT, along

with the SURP-P(42) and 4Ps+ (30) SUD screening tools via electronic questionnaire, to our

remaining sample of 150 women. Because biological tests are only able to accurately indicate

cannabis exposure for short time periods, and their reliability is dependent on dose of

exposure, there is no true gold-standard measure of the patterns of cannabis consumption

throughout pregnancy. We therefore measured concurrent validity of CEPT responses against

detailed cannabis use information revealed during the IDIs, using Cohen's kappa statistic. There

is strong evidence that through rigorous qualitative interview techniques, a trust-relationship

can be established between researcher and participant, and a high degree of truth value can be

achieved (43). We assessed discriminant validity of CEPT responses against SURP-P and 5Ps

tools using Cohen's kappa. We calculated internal consistency on all CEPT cannabis

consumption items using Chronbach's alpha, while acknowledging that it is designed to

measure multiple constructs of cannabis exposure (i.e. any use, frequency, timing, dose, mode

and reasons for consumption), rather than a single construct such as a disease state. However,

we anticipated internal consistency among the CEPT items, as a person indicating no

consumption on one item should have similar answers on all other items, and those indicating

some use should have non-zero responses for dose, mode frequency and reasons for use. We

then re-administered the tool to all participants (n=150) 3 months later to assess test-retest

reliability (agreement) using a weighted Cohen's kappa.

In an additional external sample of 24 pregnant participants, we validated CEPT responses

against urine bioassay measurements of 11-nor-9-carboxy-Δ^9- THC, the most abundant THC

metabolite. Participants provided urine samples in sterile collection containers that were

shipped frozen to our laboratory by pre-paid courier for analysis, within 24hours of completing

an online questionnaire containing the CEPT. We stored urine samples in a dedicated -80°c

freezer until analysis. 2ml aliquots were taken from thawed samples, diluted (2x) with ultrapure

water and assayed in triplicate using a 96-strip-well, THC Metabolite ELISA Kit (catalogue #

701570, Cayman Chemicals^{TM}, United States of America) according to manufacturer's protocol.

No freeze-thaw cycles were allowed.

Results:

Our sample included 175 pregnant past, current, and non-consumers of cannabis. Specific sub-

samples participated in various steps (Figure 1). Table 2 summarizes participant characteristics

at enrollment. Other sociodemographic characteristics of our sample were similar to the overall

maternal population in Canada (44–46). (Fig. 2)

Qualitative interviews:

We chose to cease qualitative data collection after completion of 10 interviews as no new ideas

were apparent under our deductive themes after analysis of the 8th transcript, indicating that

thematic saturation had been reached. Summaries of a-priori deductive themes and illustrative

quotes are presented in Table 2. Numerous important insights around bias-minimizing language

and wording, tool structure, response options, and patterns of use were gained from qualitative

results, and drove the terminology and language used in the tool preamble and questions,

guided tool structuring including inclusion of specific items (e.g. reasons for use) and response

options, and determined the method of dose measurement. While legalization was perceived

to have reduced stigma around cannabis use in general, perceptions of stigma against use in

pregnancy were prevalent and thus important for consideration to encourage accurate

disclosure. Several participants noted that including a response option to disclose cannabis

consumption that occurred only prior to pregnancy recognition was crucial, and noted that for

many, if this option was not present, they would not report any use, even if they had consumed

some cannabis prior to pregnancy recognition. One of the most challenging aspects of cannabis

consumption measurement is identifying dose. IDI results provided insight into a reliable

method of quantifying approximate dose per use (i.e. comparing amounts to common objects,

like food items or coins). Approximate THC/CBD content can be inferred based on mean THC

content of dried cannabis available on the contemporary market (24%)(47), or the labeled

concentration of products as reported by participants.(Supplementary file 2)

Cognitive interviews:

We completed cognitive interviews with a separate sub-sample of 17 participants to assess and

minimize points of bias through participant-led refinement. This resulted in 9 sequential

iterations of our initial draft tool. Perceived sources of bias at all five stages of cognition were

identified, and we made refinements to minimize the potential for biased responses based on

participant feedback, until no further changes were suggested. (Figure 2)

Question understanding: Most of the draft tool questions were well understood; however,

some changes were made to improve clarity.

Recalling relevant behaviour: All participants indicated that they were accurately able to recall

details of first-hand cannabis consumption, including frequency, trimester of consumption,

reasons, modes, and amounts per use. Nearly all participants (93%) indicated they were able to

accurately recall the details of second-hand cannabis smoke or vapour exposure, aside from

brief outdoor exposures. We amended the second-hand exposure questions to align with

exposure confirmed by previous literature to elevate THC blood-levels of the passive user to

equivalent levels in the first-hand user (48).

Inference & estimation: Participants did not express concerns about inference or estimation on

items measuring any consumption/exposure, or frequency, timing or reasons for use. Dose

questions were adjusted to address perceived ambiguity and aid with estimation (figure 2).

Mapping answers onto response options: Several participants noted problems with initial dose-

per-use response-options, increments for some product types were deemed too large for use in

pregnancy, and we refined categories to align with participant-identified appropriate ranges

and increments.

Answer editing: No participants expressed the need to edit responses once the above

clarifications and response-option edits had been made. Further, participants agreed that the

overall tool was non-judgemental, appropriate, and acceptable to them as pregnant research

participants, and that it would elicit truthful responses, confirming face and content validity

from the participant perspective.

The final refined CEPT has 9 items measuring weeks of gestation, second-hand exposure,

partner use, trimester(s) of consumption, frequency, reasons, modes of consumption, and dose

per use for each mode indicated. Frequency, reasons, modes, and dose items repeat for each

trimester of use indicated. (Appendix A)

Validity and reliability:

Content validity was deemed high by our expert reviewers, who noted the CEPT's ability to

distinguish high, single doses from sustained low dose exposure, and to capture changes in use

patterns across all trimesters.

Concurrent validity was excellent, with agreement between IDI participant CEPT responses and

use reported in IDIs, ranging from 80% to 100%, and kappa values ranging from substantial

(0.72) to perfect (1.0) (49) (Table 4). The timing of use construct showed the lowest level of

agreement, which was expected. Use will be reported in more trimesters as a pregnancy

progresses. A greater proportion of participants (40%) reported third-trimester use on the

online CEPT, compared with IDIs (30%), which occurred 5-6 weeks prior. Discriminant validation

indicated poor agreement between two pregnancy SUD screening tools (5ps and the SURP-

p)(refs), with weighted Kappa values ranging from -0.31 to 0.36 indicating that the CEPT

measures different constructs from those on the existing tools. (Table 5)

Reliability testing showed excellent internal consistency (Chronbach's alpha=0.92) and

substantial to near-perfect Kappa values (0.71-0.99) for test-retest reliability (Table 6). Although

some patterns of use may be expected to change throughout pregnancy, the strong agreement

between early and late pregnancy responses on the CEPT support that recall of cannabis

consumption using this tool is reliable up to delivery.

CEPT-reported cannabis use and/or exposure to second-hand cannabis was valid against urine-

THC bioassay in our preliminary analyses (table 5), and show much higher sensitivity (77%) than

self-report during prenatal care observed in previous studies (36%), and had 100% specificity,

indicating that it has promise as an improved measure of prenatal cannabis use for research

purposes.

Interpretation:

The CEPT addresses the measurement limitations faced by previously published studies of

prenatal cannabis consumption and associated maternal and infant health outcomes, which are

highly susceptible to misclassification bias, have inconsistent findings and are rated moderate

at best by the US National Academies of Science Engineering and Medicine(10,50). It offers

researchers a measurement option with strong validity and reliability, that accounts for

frequency of cannabis consumption, reasons for consumption, modes of consumption,

estimated dose-per-use, measures CBD and THC, and allows repeated measures per trimester

to capture changing patterns of exposure. It also captures frequency and timing of second-hand

exposure, in addition to partner's cannabis use. The CEPT thus enables more complete picture

of exposure over pregnancy than currently published studies have been able to capture. The

patient-oriented methods we used are a strength; qualitative in-depth interviews can reveal

aspects of health behaviour that contrast with the underlying assumptions held by researchers

that can unintentionally interfere with the five stages of cognition and create opportunities for

biased response (39,40). Evidence from studies on the measurement of prenatal alcohol use

indicate that non-disclosure bias for prenatal substance use varies according to participant

perceptions, and that question wording and structure informed by patient-oriented designs can

improve validity.(20,51) Further, the language used, the tone of the questions, and the

perceived intent of the tool are all critical components contributing to non-biased response.

The qualitative interviews in our study explored in-depth what was perceived as judgemental or

stigmatizing, and revealed patient-identified methods for reducing the perception of judgement

and stigma in our tool. The cognitive interviews acted to further reduce sources for perceived

stigma, thereby reducing the potential for biased responses. While we may never be able to

completely eliminate the bias arising from hesitancy to report prenatal cannabis use due to

stigma, our patient-oriented development process was chosen specifically because it is crucial

for minimising perceived stigma, and ensuring a much lower probability of bias than the

methods of measurement used in existing studies, including biological samples, which do not

allow the participant to explain their reasons for use, nor to judge the motivations of the

researchers for measuring their use of cannabis.

Although there remains no feasible gold-standard measure of prenatal cannabis consumption,

the CEPT represents a useful tool for researchers to augment the quality and expand the scope

of longitudinal research into the health outcomes associated with prenatal cannabis exposure.

Our results indicate that it has the potential to minimize self-report bias, and its nuanced

measurement of multiple dimensions of cannabis consumption may also reduce

misclassification of very low exposures, allow for assessment of potential dose-response

relationships, and enable the identification of critical windows of fetal exposure in future

studies, that were not possible with previous crude measures.

Limitations: The CEPT is designed to measure behaviours over pregnancy, rather than to detect

a condition or health state. Where medical screening tools can be validated against diagnostic

tests or interviews, validating a measure of behaviour is more complex. A limitation of our

study is the lack of a true gold-standard measure of cannabis consumption patterns throughout

pregnancy for validation, which would require at least weekly serial urine collection throughout

gestation, which was financially infeasible for this study. However, we have preliminarily

validated CEPT responses against a biological reference-standard, showing very good sensitivity

and excellent specificity. While we could not attain a true biological gold-standard in our study,

the validation we conducted against single bioassays, and in-depth qualitative interviews

remains a rigorous method. Biological levels of THC metabolite cannot be falsified, and the

qualitative methods we employed result in high credibility and truth-value for qualitative

results (57). Further, IDIs allowed for comparison of binary cannabis use as well as multiple

aspects of cannabis consumption patterns (modes, frequency, timing) that are more difficult

with a biological test comparator. Although our study sample was adequate to detect a

Cronbach's alpha of ≥ 0.9 on a tool with up to 15 items, we acknowledge that our overall sample

and the preliminary bioassay validation sample (n=24) was small. Future validation studies

should include larger samples to confirm findings. It is also important to note that our tool and

the validation conducted are limited to English-speaking populations, and translations will

require further validation. Additionally, cultural differences may impact the interpretations of

participants and use in non-Canadian settings should also be validated separately.

Conclusion:

Prenatal cannabis use and its associated health outcomes have been identified as priorities for

research in Canada following cannabis legalization.(9) We recommend the CEPT as a rigorous,

feasible, patient-oriented health research tool for measuring prenatal cannabis consumption.

The use of the CEPT as a standardized measure of prenatal cannabis consumption in future

studies can contribute substantial new knowledge about the implications of timing, dose,

frequency, and modes of exposure for maternal, fetal, infant and child health, accounting for

varying patterns of consumption and the strength and diversity of cannabis products available

on the contemporary Canadian market. The CEPT has the potential to significantly improve

measurement accuracy and thus the quality of research in this area, which can in turn inform

evidence-based education, prevention and health policy to mitigate potential health risks.

Data sharing: Quantitative data can be made available in accordance with the ethics approval

for the study, on reasonable request to the corresponding author.

347   *Table 1: Measurement domains of existing prenatal cannabis measurement options*

Includes measure of:	4ps	4ps+	WIDUS	CRAFFT	SURP-P	StatsCan	Generation-R	NSDUH
Cannabis separately	no	no	no	yes	yes	yes	yes	yes
Use in pregnancy	no	yes	no	No	no	no	yes	*indirect
Frequency of use	no	no	no	no	no	yes	yes	yes
Timing of use in pregnancy	no	no	no	no	no	no	1st trimester & pre-preg.	*indirect
Dose	no	no	no	no	no	yes	no	no
Mode of consumption	no	no	no	no	no	yes	no	no
Medicinal vs. recreational use	no	no	no	no	no	yes	no	no
Time-span covered	Past ever	Past month	Past ever	Past 12 months	Past ever	Past 3 months	Pre-pregnancy, First trimester	*Past 3 mos.
Second-hand exposure/partner use	yes	yes	yes	no	yes	no	yes	no
Reference	(56)	(28)	(57)	(58)	(40)	(60)	(61)	(37)

4Ps=Parent drug problem, Partner drug problem, Past use of substance
4Ps+= Parent drug problem, Partner drug problem, Past use of substance, Pregnancy use
WIDUS= Wayne Indirect Drug Use screener; CRAFFT = Car, Relax, Alone, Forget, Friends, Trouble;
SURPP= substance use risk in pregnancy profile; NSDUH = National Survey on Drug Use and
*Health; StatsCan = Statistics Canada * specific date can be cross-referenced with pregnancy*
information if provided

Variable	Proportion % (n)	95% Confidence Interval	Mean	Range
Gestational age			27 weeks	8-36 weeks
1st trimester	4	1.9 - 9.2		
2nd trimester	41.5	33.6 - 49.9		
3rd trimester	54.2	45.9 - 62.3		
Parity			1	0-5
nulliparous	37 (63)	29 - 45		
multiparous	63 (107)	54.9 – 70.1		
Maternal Age				
<35	83 (141)	*		
≥35	17 (29)	*		
Female gender	100 (170)			
Ethnicity				
Caucasian	84.1 (23)	77 - 89		
Non-Caucasian	15.9 (121)	11 - 22		
Residence				
Urban	75 (128)	67 – 81		
Rural	25 (42)	19 - 33		
Home ownership				
Owns home	52 (88)	42 - 58		
Rent/other	48 (82)	41 - 57		
Marital Status				
Married or common-law	78 (133)	77 - 79		
other	22 (38)	18 - 26		
Annual Household Income				
< $60,000	59	52 - 67		
$60,000 or more	41	33 - 48		

377   * Only aggregate age category available

380   Table 3: Deductive themes and illustrative quotes *(n=10)*

Theme 1 - Language/wording: Participants indicated that non-judgemental wording around cannabis use as well as specific terms and context affected their choice to disclose their cannabis use while pregnant.
"…say "cannabis" instead of marijuana, because I think of marijuana only being the plant… not edibles, or cbd and lip balm, or whatever."
"Why you want to know is important. I would be way more up-front if I know it's for research, than like, if they want to know at the hospital…"
"If someone sounds judgmental, that would make me not want to discuss it. If it's something that it's

	clear that they're open to it, … I would be like, yeah, here's how I take it and why."
	"I wouldn't say 'use', I would say 'consume'. [use] has a bit of a negative to it."
	"[marijuana] sometimes has a negative connotation, like it's a drug, but cannabis is more … like it's natural."

Theme 2a) Tool structure - General: The need for non-judgemental wording, and for cannabis to be treated separately from other substances on a questionnaire were identified as essential to avoid biased responses.

	"Say something at the beginning to make it clear that you're not judging. If it sounds judgmental, or like, if I think you're asking me so you can lecture me … someone's judging me for using it, I wouldn't answer."
	"I feel like if doctors were a little non-judgmental and a little less biased, then it would create some more honesty."
	"If it's lumped in with, you know, smoking, then drinking, then marijuana, then …heroin and cocaine, that just gives it a real negative tone… like, it's worse than alcohol, and almost as bad as heroin… I wouldn't be answering, really, if it's like that."
	"it makes more sense to me to have it with… supplements, or alternative therapies."

Theme 2b) Tool structure - Response options: Allowing participants to indicate their reasons for consuming cannabis in pregnancy (which were predominantly reported as medicinal), was perceived as a key factor for encouraging honest disclosure. A response option indicating that use only took place prior to pregnancy recognition was also seen as essential to unbiased reporting.

	"I believe the stigma has died a lot. But there is still a big stigma with pregnancy for some people."
	"Especially in the first pregnancy women feel a lot more judged."
	"I don't believe it should be used in pregnancy to get stoned, or to get high. But I believe that if it's going to help with morning sickness, or relieve pain, or anything that you're going through that may cause you suffering or stress, I believe it safe to use…"
	"some people stop as soon as they find out [they're pregnant], so you need to be able to say that."

Theme 3a) Patterns of use – Mode of consumption: Participants indicated numerous modes of consumption (vapour, oral/edible, topical, cannabidiol (CBD)) with varying doses for each, and some perceived as safer in pregnancy than others, supporting the need for standardized measurement of consumption-routes beyond smoking.

	"I would think that ingesting it… would be a lot safer [than smoking] because there's less transfer to the fetus."
	"I think edibles and lotions and liquid CBD capsules even, they're most likely more safe to take during pregnancy considering just that you're taking out the smoking out of the equation"
	"I don't necessarily think that smoking it is the smartest."
	"I mostly smoke, but I have drops and a lotion too."
	"… for vaping it, [I] stick to three puffs maximum when it comes to THC products."
	"Smoking does work quite quickly, especially for morning sickness. But a tincture can work…"
	"I consume CBD oil daily, as well as smoking [cannabis]."

Theme 3b) Patterns of use – Frequency and Timing: Participants consistently indicated their patterns of use changed during pregnancy to a more frequent consumption of smaller amounts, compared to their general use pre-pregnancy, indicating that tool response options need to include high frequencies (i.e. multiple times per day) and small dose-per-use categories, compared to existing survey questions.

	"I use it different (sic) now that I'm pregnant… I have a quick drag whenever I need it, so 3 or 4 times a day sometimes, but just a tiny bit, instead of having a lot at once."
	"…I resumed micro-dosing daily…"
	"I think asking about frequency makes sense - most people use it pretty regular (sic)"

Theme 3b) Patterns of use – Dose: Amounts of cannabis typically consumed at each sitting was discussed primarily in subjective terms (i.e. large, small), perceptions of which may vary considerably between consumers, and identifying the weights or exact doses used at each sitting was perceived as difficult or infeasible, particularly for dried cannabis. Comparison measures were preferred.

	"I know how much I buy by weight, but I couldn't tell you the grams I put in the pipe yesterday evening..."
	"With smoking it, it's harder... like, a big joint for me might not be big for my sister."
	"It's easy if it's an edible, because it tells you on the label…"
	"The THC oil that I have is 30 milligrams per mil, so that would work out to being about point three milligrams for point one or point two of a milliliter."
	"Maybe start at half a milliliter, so that would be what? More like 10 milligrams, I guess, of the 40 milligram [per milliliter] stuff that I have."
	"I would say the easiest way for people to say how much they smoke would be like a pea-sized amount, or a grape-size…compare it to something. Then you could figure out the grams from that. I don't know how many grams or milligrams I use every time."
	"I might use a small dab like the size of a dime, or other times it might be like twice as much…"

386   Table 4: Concurrent validity of the CEPT vs. In-depth interview (*n=10*)

	Agreement		Kappa	Std. Error	P-Value
Construct	actual	expected			
Any use in pregnancy	100%	82%	1.00	0.31	>0.001
Frequency of use	90%	22%	0.87	0.16	>0.001
Timing (trimester)	80%	28%	0.72	0.19	>0.001
Mode of consumption	100%	22%	1.00	0.21	>0.001

388   Table 5: Discriminant validity of CEPT versus SUD screening tools (n=153)

	CEPT Agreement		Kappa	Std. Error	P-Value
Screening Tool	actual	expected			
5Ps	44.9%	45.1	-0.031	0.04	0.53
SURP-P	69.8%	52.3%	0.36	0.08	0.01

389   Legend: Compares positive SUD screening result with any prenatal cannabis use on CEPT

394 Table 6: Test-retest reliability of the CEPT - 3-month interval *(n=153)*

Construct	Agreement		Kappa	Std. Error	P-Value
	actual	*expected*			
Any second-hand exposure	92%	52%	0.83	0.08	>0.001
Any use in pregnancy	97%	51%	0.95	0.08	>0.001
Frequency of use	90%	28%	0.86	0.04	>0.001
Timing (trimester)	80%	32%	0.71	0.05	>0.001
Mode of consumption	99%	51%	0.97	0.08	>0.001

396 Table 7: Preliminary Validity of the CEPT against Biological THC

	Bioassay negative	Bioassay positive	Total
CEPT negative	8	4	12
CEPT positive*	0	13	13
Total	8	17	**25**

Measure:		95% confidence interval
Sensitivity:	76.5%	59.84% - 93.10%
Specificity:	100%	100.00% - 100.00%
PPV:	100%	100.00% - 100.00%
NPV:	66.7%	48.19% - 85.15%

397 *positive prenatal exposure includes any cannabis use and/or second-hand exposure during pregnancy

400
401 <u>Figure 1: Study Process Flow Diagram</u>
402

```
                          ┌────────────────────────────────────────┐
                          │        Full Study Sample (N=195)        │
                          └────────────────────────────────────────┘
 ┌──────────────┐
 │ Environmental │
 │     scan      │
 └──────────────┘         ┌────────────────────┐
                          │ Individual In-depth │
                          │  Interviews (n=10)  │
 ┌──────────────┐         └────────────────────┘
 │ Tool drafted  │
 └──────────────┘                               ┌────────────────────┐
                                                │ Cognitive Interviews│
                                                │      (n=17)         │
                                                └────────────────────┘
 ┌──────────────┐
 │ Tool revised  │
 └──────────────┘

 ┌──────────────┐
 │Content Validation│
 └──────────────┘         ┌────────────────────────────────────────┐
                          │ First administration of final tool (n=153)│
                          └────────────────────────────────────────┘
 ┌──────────────────┐
 │   Concurrent      │
 │ Validation (n=10) │
 └──────────────────┘
 ┌──────────────────┐
 │   Discriminant    │
 │ Validation (n=153)│
 └──────────────────┘
 ┌──────────────────┐
 │    Internal       │
 │   Consistency     │
 └──────────────────┘      ┌────────────────────────────────────────┐
                           │ 2nd administration of final tool (n=150) │
                           └────────────────────────────────────────┘
 ┌──────────────────┐
 │   Test-retest     │                          ┌────────────────────┐
 │ reliability (n=150)│                          │Lost to follow-up (n=3)│
 └──────────────────┘                          └────────────────────┘
                           ┌────────────────────────────────────────┐
                           │ 3rd administration of final tool + urine sample │
                           │             (external n=25)             │
                           └────────────────────────────────────────┘
 ┌──────────────────┐
 │ Sensitivity and   │
 │ specificity (n=25)│
 └──────────────────┘
```

<u>Figure 2: Participant Characteristics Versus Maternal Population of Canada</u>

Figure 3: Cognitive Interviews - Bias reduction for the five stages of cognition
References:

1. Young-Wolff KC, Sarovar V, Tucker LY, Avalos LA, Alexeeff S, Conway A, et al. Trends in

marijuana use among pregnant women with and without nausea and vomiting in

pregnancy, 2009–2016. Drug Alcohol Depend. 2019;196:66–70.

2. Corsi DJ, Hsu H, Weiss D, Fell DB, Walker M. Trends and correlates of cannabis use in

pregnancy: a population-based study in Ontario, Canada from 2012 to 2017. Can J Public

Heal Can Sante Publique. 2018;Nov 1.

3. Luke S, Hutcheon J, Kendall T. Cannabis Use in Pregnancy in British Columbia and

Selected Birth Outcomes. J Obstet Gynaecol Canada. 2019;

4. Corsi DJ, Walsh L, Weiss D, Hsu H, El-Chaar D, Hawken S, et al. Association between Self-

reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA

- J Am Med Assoc. 2019;

5. El Marroun H, Tiemeier H, Steegers EAP, Jaddoe VW V, Hofman A, Verhulst FC, et al.

Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R

Study. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1173–81.

6. Marroun H El, Hudziak JJ, Tiemeier H, Creemers H, Steegers EAP, Jaddoe VWV, et al.

Intrauterine cannabis exposure leads to more aggressive behavior and attention

problems in 18-month-old girls. Drug Alcohol Depend. 2011;

7. Stickrath E. Marijuana Use in Pregnancy: An Updated Look at Marijuana Use and Its

Impact on Pregnancy. Clin Obstet Gynecol. 2019;

8. Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: A review of the

evidence. Vol. 213, American Journal of Obstetrics and Gynecology. 2015. p. 761–78.

9. Porath-Waller AJ. Clearing the Smoke on Cannabis Series: Maternal Cannabis Use during

Pregnancy. Can Cent Subst Abus. 2015;1–8.

10.   Board on Population Health and Public Health Practice, Health and Medicine Division,

National Academies of Sciences Engineering and Medicine. The Health Effects of

Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for

Research [Internet]. The Health Effects of Cannabis and Cannabinoids: The Current State

of Evidence and Recommendations for Research. 2017. 440 p. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/28182367

11.   Torres CA, Medina-Kirchner C, O'Malley KY, Hart CL. Totality of the Evidence Suggests

Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and

Critical Review. Front Psychol. 2020;

12.   Chaput KH, Lebel CA, McMorris CA. Commentary: Totality of the Evidence Suggests

Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and

Critical Review. Front Psychol. 2020;tbd(e-pub).

13.   Center for Behavioral Health Statistics and Quality. Results from the 2012 National

Survey on Drug Use and Health. 2013.

14.   Roberts SCM, Nuru-Jeter A. Women's Perspectives on Screening for Alcohol and Drug

Use in Prenatal Care. Women's Heal Issues. 2010;20(3):193–200.

15.   Ernhart CB, Morrow-Tlucak M, Sokol RJ, Martier S. Underreporting of alcohol use in

pregnancy. Alcohol Clin Exp Res. 1988;12(4):506–11.

16.   Holland CL, Nkumsah MA, Morrison P, Tarr JA, Rubio D, Rodriguez KL, et al. "Anything

above marijuana takes priority": Obstetric providers' attitudes and counseling strategies

regarding perinatal marijuana use. Patient Educ Couns. 2016;99(9):1446–51.

17.   Kaarid KP, Vu N, Bartlett K, Patel T, Sharma S, Honor RD, et al. Assessing the prevalence

and correlates of prenatal cannabis consumption in an urban Canadian population: a

cross-sectional survey. Can Med Assoc Open Access J [Internet]. 2021;9(2):E703--E710.

Available from: https://www.cmajopen.ca/content/9/2/E703

18.   Chang JC, Holland CL, Tarr JA, Rubio D, Rodriguez KL, Kraemer KL, et al. Perinatal illicit

drug and marijuana use: An observational study examining prevalence, screening, and

disclosure. Am J Heal Promot. 2017;31(1):35–42.

19.   Hannigan JH, Chiodo LM, Sokol RJ, Janisse J, Ager JW, Greenwald MK, et al. A 14-year

retrospective maternal report of alcohol consumption in pregnancy predicts pregnancy

and teen outcomes. Alcohol. 2010;44(7–8):583–94.

20.   Chiodo LM, Sokol RJ, Delaney-Black V, Janisse J, Hannigan JH. Validity of the T-ACE in

pregnancy in predicting child outcome and risk drinking. Alcohol [Internet]. 2010/01/06.

2010;44(7–8):595–603. Available from: https://pubmed.ncbi.nlm.nih.gov/20053522

21.   Rotermann M, Pagé MM. Prevalence and correlates of non-medical only compared to

self-defined medical and non-medical cannabis use, Canada, 2015. Heal Reports.

2018;29(7):3–13.

22.   Singer LT, Arendt R, Fagan J, Minnes S, Salvator A, Bolek T, et al. Neonatal visual

information processing in cocaine-exposed and non-exposed infants. Infant Behav Dev.

1999;

23.   Fried PA, Watkinson B. 36- and 48-month neurobehavioral follow-up of children

prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr. 1990;

24.   Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, et al. Effect of

prenatal marijuana exposure on the cognitive development of offspring at age three.

Neurotoxicol Teratol. 1994;

25.   el Marroun H, Tiemeier H, Jaddoe VWV, Hofman A, Mackenbach JP, Steegers EAP, et al.

Demographic, emotional and social determinants of cannabis use in early pregnancy: The

Generation R study. Drug Alcohol Depend. 2008;

26.   Office of Research and Surveillance. Canadian Tobacco Alcohol and Drugs (CTADS): 2015

summary [Internet]. CTADS 2015. 2017. Available from:

https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-

survey/2015-summary.html

27.   Coleman-Cowger VH, Schauer GL, Peters EN. Marijuana and tobacco co-use among a

nationally representative sample of US pregnant and non-pregnant women: 2005–2014

National Survey on Drug Use and Health findings. Drug Alcohol Depend. 2017;177.

28.   Leos-Toro C, Rynard V, Hammond D. Prevalence of problematic cannabis use in Canada:

Cross-sectional findings from the 2013 Canadian Tobacco, alcohol and drugs survey. Can

J Public Heal. 2017;108(5–6):e516–22.

29.   Gotman N, Kershaw T, Rounsaville BJ, Forray A, Howell HB, Yonkers KA. Screening for

Prenatal Substance Use. Obstet Gynecol. 2010;116(4):827–33.

30.   Chasnoff IJ, Wells AM, McGourty RF, Bailey LK. Validation of the 4P's Plus© screen for

substance use in pregnancy validation of the 4P's Plus. J Perinatol. 2007;27(12):744–8.

31.   Ondersma SJ, Svikis DS, Lebreton JM, Streiner DL, Grekin ER, Lam PK, et al. Development

and preliminary validation of an indirect screener for drug use in the perinatal period.

Addiction. 2012;107(12):2099–106.

32. Harris SK, Knight JR, Van Hook S, Sherritt L, L Brooks T, Kulig JW, et al. Adolescent

substance use screening in primary care: Validity of computer self-Administered versus

clinician-Administered screening. Subst Abus. 2016;37(1):197–203.

33. Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for

prenatal substance use: Development of the substance use risk profile-pregnancy scale.

Obstet Gynecol. 2010;116(4):827–33.

34. James WH, Moore DD. Examining the Relationship between Gender and Drug-Using

Behaviors in Adolescents: The Use of Diagnostic Assessments and Biochemical Analyses

of Urine Samples. J Drug Educ. 2005;29(3):235–49.

35. Mura P, Kintz P, Papet Y, Ruesch G, Piriou A. [Evaluation of six rapid tests for screening of

cannabis in sweat, saliva and tears]. Acta Clin Belg. 1999;53 Suppl 1:35–8.

36. Pippins JR, Brawarsky P, Jackson RA, FuentesAfflick E, Haas JS. Association of

Breastfeeding with Maternal Depressive Symptoms. J Women's Heal [Internet]. 2006

Jul;15(6):754–62. Available from: http://Haas, Jennifer S.: jhaas@partners.org

37. Riley KJ, Lu NT, Taylor BG. Drug screening: A comparison of urinalysis results from two

independent laboratories. J Drug Issues. 2000;30(1):171–86.

38. Earleywine M. Understanding Marijuana: A New Look at the Scientific Evidence.

Understanding Marijuana: A New Look at the Scientific Evidence. 2010. 1–341 p.

39. Streiner DL, Norman GR. , John Cairney Health Measurement Scales: A Practical Guide To

Their Development and Use, January 2015 Edition: 5th Publisher: Oxford University Press

ISBN: 0199685215 DOI:10.1093/acprof:oso/9780199231881.003.0006,

40.   Schwarz N, Oyserman D. Asking questions about behavior: Cognition, communication,

522   and questionnaire construction. Am J Eval. 2001;22(2):127–60.

523   41.   Willis G, Lessler J. Question Appraisal System (QAS 99 Manual). 1999.

524   42.   Coleman-Cowger VH, Oga EA, Peters EN, Trocin K, Koszowski B, Mark K. Comparison and

525   validation of screening tools for substance use in pregnancy: A cross-sectional study

526   conducted in Maryland prenatal clinics. BMJ Open. 2018;8(2).

527   43.   Sale J, Brazil K. A strategy to identify critical appraisal criteria for primary mixed methods

528   research. Qual Quan. 2004;38:351–65.

529   44.   Canada. PHA of. Data Tables - The Maternity Experiences Survey (MES) 2006 - 2007

530   [Internet]. Vol. 2012. 2009. Available from: http://www.phac-aspc.gc.ca/rhs-ssg/pdf/tab-

531   eng.pdf

532   45.   Teubert D, Pinquart M, Pinheiro MIS, Haase VG, Del Prette A, Amarante CLD, et al. NIH

533   Public Access. Eur J Psychotraumatol [Internet]. 2015;15(1):No-Pagination Specified.

534   Available from: http://www.repositorio.ufc.br/bitstream/riufc/7744/1/2014-DIS-

535   ASMGRANGEIRO.pdf%0Ahttp://files/5407/GRANGEIRO,

536   2014.pdf%0Ahttp://files/5404/rocha, marina teses

537   ysr.pdf%0Ahttp://linkinghub.elsevier.com/retrieve/pii/S0890856716302167%0Ahttp://fil

538   es/5400/ache

539   46.   No Title [Internet]. Vol. 2019. 2019. Available from:

540   https://www.nbs.go.tz/index.php/en/census-surveys/population-and-housing-

541   census/178-tanzania-total-population-by-district-regions-2016-2017

542   47.   ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis

543   potency over the last 2 decades (1995-2014): Analysis of current data in the United

544   States. Biol Psychiatry. 2016;

545   48.   Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis

546   smoke exposure and oral fluid testing. J Anal Toxicol. 2004;

547   49.   Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.

548   Biometrics [Internet]. 1977 Jun 22;33(1):159–74. Available from:

549   http://www.jstor.org/stable/2529310

550   50.   The National Academies of Science Engineering. The health effects of Cannabis and

551   Cannabinoids. Committee's conclusions. The National Academies of Science Engineering

552   and Medicine. Natl Acad Press [Internet]. 2018; Available from:

553   http://www.dictionary.com/browse/weight

554   51.   Sokol RJ, Martier SS, Ager JW. The T-ACE questions: Practical prenatal detection of risk-

555   drinking. Am J Obstet Gynecol. 1989;160(4):863–70.

556   52.   De Giovanni N, Fucci N. The Current Status of Sweat Testing For Drugs of Abuse: A

557   Review. Curr Med Chem. 2013;20(4):545–61.

558   53.   Berg M. Status of research on gender differences in pharmacokinetics. J Am Pharm

559   Assoc. 1997;37:43–56.

560   54.   Harris R, Benet L, Schwartz J. Gender effects in pharmacokinetics and

561   pharmacodynamics. Drigs. 1995;50:222–39.

562   55.   Mattison D, Malek A, Cistola C. Physiologic adaptations to pregnancy: Impact on

563   pharmacokinetics. In: Yaffe S, Aranda J, editors. Pediatric Pharmacology: Therapeutic

564   principles in practice. Philidelphia: W.B. Saunders; 1992. p. 81–96.

565   56.   Amon I, Huller H. Dose-response relationship as a basis for choice of drugs in pregnancy

566   and for dosage calculation. In: Kuemmerle H, Brendel K, editors. Clinical pharmacology in

567   pregnancy: Funda- mentals and rational pharmacotherapy. Nwe York: Thieme-Stratton;

568   1984. p. 64–73.

569   57.   Lincoln Y, Guba NJ. Naturalistic inquiry. Vol. 1. Beverly Hills: Sage Publications; 1985.